Modulated Light Therapy in Participants With Pattern Hair Loss

NCT ID: NCT04019795

Last Updated: 2024-09-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 160 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-01-05
• Study Completion Date: 2019-05-25

Brief Summary

The REVIAN study is designed as a prospective, randomized, controlled, double-blind, parallel study to evaluate the efficacy and safety of the REVIAN System in male participants with androgenic alopecia. An Active modulated light therapy REVIAN System will be compared to a Placebo Comparator non-active REVIAN System in participants using the device for a daily 10-minute treatment over the course of 26-weeks. At each follow-up visit, participants will be interviewed to determine if any adverse events (AEs) were experienced since the previous follow-up visit. All participants will be required to complete self-administering scalp hair growth and life quality questionnaires at each follow-up visit. Investigators will be required to complete global assessments of scalp hair growth for each enrolled participant at each follow-up visit. Macrophotography evaluations will be performed at baseline, 8-, 16-, and 26 weeks for all participants using standard Canfield blinded reviewer. Global photographs of superior and vertex scalp will be taken by participants and by PI to be assessed by a blinded reviewer once all photos have been captured for each participant per visit.

Conditions

Androgenetic Alopecia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Non-Active REVIAN (Sham) Cap 100

Sham (Control) Group

Group Type: SHAM_COMPARATOR

REVIAN 100

Intervention Type: DEVICE

The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.

REVIAN 100 contains LEDs that are not powered for light therapy

Active REVIAN Cap 101

(625 nm and 660 nm)

Group Type: EXPERIMENTAL

REVIAN 101

Intervention Type: DEVICE

The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.

REVIAN 101 delivers 625 nm and 660 nm wavelengths of red light.

Active REVIAN Cap 102

(425 nm)

Group Type: EXPERIMENTAL

REVIAN 102

Intervention Type: DEVICE

The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.

REVIAN 102 delivers 425 nm wavelength of blue light.

Active REVIAN Cap 103

(425 nm, 625 nm and 660 nm)

Group Type: EXPERIMENTAL

REVIAN 103

Intervention Type: DEVICE

The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.

REVIAN 103 delivers 425 nm wavelength of blue light and 625 nm and 660 nm wavelengths of red light.

Interventions

REVIAN 101

The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.

REVIAN 101 delivers 625 nm and 660 nm wavelengths of red light.

Intervention Type: DEVICE

REVIAN 102

The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.

REVIAN 102 delivers 425 nm wavelength of blue light.

Intervention Type: DEVICE

REVIAN 103

The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.

REVIAN 103 delivers 425 nm wavelength of blue light and 625 nm and 660 nm wavelengths of red light.

Intervention Type: DEVICE

REVIAN 100

The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.

REVIAN 100 contains LEDs that are not powered for light therapy

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• The study population will consist of adult men and women between 18 and 65 years of age with diagnosis of Androgenic Alopecia, consistent with males who have Norwood Hamilton Classification IIa to V patterns of hair loss and females who have Ludwig-Savin Scale I-1 to I-4, II -1, II-2 or frontal, both with Fitzpatrick Skin Types I - IV. Participants agree to undergo all study procedures including global photographs of hair loss/growth, placement of a 1 mm tattoo dot placed on the scalp for macrophotography, refrain from using all other hair growth products or treatments (oral or topical medication including over the counter herbal medications, or Dutasteride), avoid the use of wigs, hairpieces, and/or hair extensions during the study, return for all the required follow-up visits, and in the opinion of the Clinical Investigator, are able to understand this clinical investigation and cooperate with the investigational procedures.

Candidates for this study must meet ALL of the following criteria:

1. Male and Female participants between 18 and 65 years of age

2. Must be able to read and speak English.

3. Participants who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.

4. Participants, who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, cooperate with the investigational procedures and are willing to return for all the required follow-up visits.

5. Participant must be able to visit clinic site at 8-, 16- and 26-weeks study visits and be available by phone at 4 weeks.

6. Participant must have the ability to communicate effectively with study personnel in person or over the phone.

7. Participant must have diagnosis of Androgenic Alopecia (pattern hair loss).

8. Participant must have active hair loss consistent with Grades IIa to V, based on Norwood- Hamilton Scale or Ludwig-Savin Scale I-1 to I-4, II -1, II-2 or frontal and Grades I - IV using Fitzpatrick Skin Type Scale.

9. Participant's hair must be at least 1 inch in length. The hair style and length shall be the same for each follow-up visit. Participants will be instructed to not have their hair cut/styled within 5 days prior to a follow-up visit.

10. Participant is willing to have a dot tattoo placed on or around the target area of the scalp.

11. Participant is willing to undergo all study procedures including consent for global photographs of hair loss/growth and a 1 mm tattoo to mark the macrophotography site along the indicated transition area of the scalp between the hairline and the balding/thinning vertex area.

12. Participant is willing to avoid the use of wigs, hairpieces, and/or hair extensions during the study period.

13. Hair Specific Skindex-29 Quality of Life total overall score of ≥ 45.

14. Participant is willing to maintain their natural hair colour or including the use of coloring throughout the study period.

15. Participant agrees to refrain from using all other hair growth products or treatments (oral or topical medication including over the counter herbal medications, or Dutasteride) during the study period.

16. Participant has the ability to utilize a Bluetooth device and application on a smart device connected to Wi-Fi.

Exclusion Criteria

• Participants with 12 month history of taking Propecia or any other hair growth supplements including Rogaine or Minoxidil based products for 6-months prior to enrollment, having previous hair transplant, cell treatment, micro-needling, tattooing, or any other treatment to the scalp, suffering from an active autoimmune disease such as serum lupus erythematosus or alopecia areata, photosensitivity to visible light, currently suffering from a dermatological condition in the treatment area or has a significant scar in the hair treatment area that will make hair growth difficult (such as a systemic burn, malignancy, etc.), has a sensitivity or allergy to tattoo ink, using any medication deemed to inhibit hair growth as determined by the physician investigator, or have had radiation or chemotherapy in the last 12 months will be excluded.

Candidates will be excluded from the study if ANY of the following apply:

1. Female participants of childbearing potential who are not on some form of birth control and do not have a confirmed negative pregnancy test at baseline

2. Use of Propecia or any other hair growth supplements within 12 months prior to enrollment.

3. Use of Rogaine or Minoxidil based products within 6 months prior to enrollment.

4. Participants have a previous hair transplant, cell treatment, micro needling, tattooing, or any other treatment to the scalp.

5. Participant is suffering from an active autoimmune disease such as lupus erythematosus (systemic and cutaneous) or alopecia areata.

6. Photosensitivity to visible light operating within 400 - 850 nm or taking medication that REVIAN® Trial Confidential and Proprietary Page 23 of 55 Version 6.0 2018-08-22 increases photosensitivity.

7. Currently suffering from a dermatological condition in the treatment area or has a significant scar in the hair treatment area that, in the opinion of the investigator, will make hair growth difficult (such as a systemic burn, malignancy, etc.)

8. Participant has a sensitivity or allergy to tattoo ink.

9. Using any medication deemed to inhibit hair growth as determined by the physician investigator.

10. Employed by the sponsor, clinic site, or entity associated with the conduct of the study.

11. Has had radiation or chemotherapy in the last 12 months.

12. Have any condition or situation which, in the Investigator's opinion, puts the participant at significant risk, could confound the study results, or may interfere significantly with the participant's participation in the study.

13. Known prior inability to complete required study visits during treatment period;

14. Use of any other investigational drug, therapy, or device within the past 30 days of enrollment or concurrent participation in another research study;

15. Are unable to communicate or cooperate with the Investigator due to language problems, poor mental development, or impaired cerebral function;

16. Participants who are currently involved in any investigational drug or device trial or have been enrolled in such trials within the last 3 months.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Avania

INDUSTRY

Sponsor Role: collaborator

Applied Statistics and Consulting

INDUSTRY

Sponsor Role: collaborator

Trilogic

INDUSTRY

Sponsor Role: collaborator

Catalyst Pharmaceutical Research

INDUSTRY

Sponsor Role: collaborator

PhotonMD, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rodney D Sinclair, MD

Role: PRINCIPAL_INVESTIGATOR

Sinclair Dermatology

Locations

The Skin Hospital

Darlinghurst, New South Wales, Australia

Premier Specialists

Kogarah, New South Wales, Australia

Sinclair Dermatology

Sydney, New South Wales, Australia

Veracity Clinical Research Pty Ltd

Woolloongabba, Queensland, Australia

Countries

Australia

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

REVIAN Trial

Identifier Type: -

Identifier Source: org_study_id